Drugmakers Roche and Sanofi talk up their pipelines, as earnings fail to excite
The drugmaker's full-year results didn't seem to move the needle for investors who are instead focused on future growth prospects and innovation
TL;DR
- Roche and Sanofi's latest earnings met expectations, with both companies highlighting their drug development pipelines.
- Both companies face a 'patent cliff,' necessitating the development or acquisition of new drugs.
- Roche forecasts 2026 profit growth to exceed sales growth, with up to 19 new medicines planned for launch by 2030.
- Roche reported positive Phase 2 results for its obesity drug candidate CT-388, aiming to differentiate in a competitive market.
- Sanofi reported a quarterly beat on sales and earnings, supported by new medicines and Dupixent.
- Sanofi also anticipates high single-digit sales growth in 2026 and is prioritizing R&D investment and potential M&A.
- Both companies are investing in the 'next generation' of medicines, with Roche focusing on combination therapies for various conditions.